Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Fierce Pharma
Big Pharma bets big on MASH with a new combo playbook
GSK, Roche and Novo jumped into MASH with a multibillion-dollar deal spree. Now, the phase 3 data have to deliver.
Ayla Ellison
Oct 17, 2025 9:30am
Novo Nordisk pens $2.1B deal for Omeros’ stalled PNH drug
Oct 15, 2025 9:02am
Novo Nordisk Foundation pledges $31M for pandemic preparedness
Oct 14, 2025 10:00am
Novo ends all cell therapy R&D, lets go of staff
Oct 10, 2025 3:30pm
Novo inks $4.7B Akero buyout to bag late-phase MASH prospect
Oct 9, 2025 8:21am
Skye's CB1 blocker fails to reduce weight in obesity study
Oct 6, 2025 7:55am